-
22nd Century Group (XXII) Reports Q3 Revenue of $19.4M, Net Loss of $13.1M
-
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Third Quarter 2022
-
Cowen on 22nd Century Group (XXII): 'GVB provides an attractive platform for XXII to build on its existing capabilities in cannabis'
-
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Second Quarter 2022
-
22nd Century Group (XXII) Begins Integration of GVB Biopharma
-
22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform

